• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » SRI International opens clinical trial unit in Michigan

SRI International opens clinical trial unit in Michigan

October 27, 2014
CenterWatch Staff

SRI Biosciences, a division of SRI International, a California-based independent nonprofit research institute, has completed construction of an early-phase clinical trial facility in Plymouth, Mich. The 9,400-square-foot unit, located in the Michigan Life Science Innovation Center, now is open and fully equipped for early-stage human research studies of new medicines and medical devices. 

The new purpose-built facility includes 13 beds and three infusion chairs, a state-of-the-art investigational pharmacy with the capacity to prepare sterile infusions, a laboratory for sample processing, amenities to accommodate extended overnight stays for research participants and equipment to monitor and protect the safety of these volunteers. 

The staff offers strategic development support to biotech and device companies, academic investigators and other collaborators. SRI Biosciences will help innovators with limited development infrastructure refine target product profiles that address specific unmet medical needs and optimize development strategy to maximize efficiency and minimize risk.

"Our core focus will be translational medicine research—that important stage when scientific breakthroughs move from the lab to the clinic and where their potential to improve human health can be initially evaluated," said David Sahner, M.D., senior director of clinical translation, SRI Biosciences. "When done well, early-phase clinical trials can provide critical insights—into safety, tolerability, absorption, distribution and elimination of drugs and biologics, as well as early assessment of mechanistic and therapeutic effects—that help reduce drug development risk, pave the way for future regulatory and commercial success, and get new medicines to patients who need them more quickly."

The SRI unit is equipped to perform studies involving healthy volunteers and patients with a variety of underlying diseases. SRI will leverage its extensive organizational capabilities in biomedical research, including core competencies in biomarker assay development and validation and clinical-trial product manufacturing, to facilitate the design and completion of clinical projects. SRI Biosciences also will develop its own compounds at the new facility.

In 2012 and 2013, the Michigan Strategic Fund approved a $5 million grant through the Centers of Innovation program and an $800,000 Michigan Business Development Program performance-based grant to support the project.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing